selpercatinib 80 MG Oral Tablet
- RxCUI
- 2679815
- RxNorm name
- selpercatinib 80 MG Oral Tablet
- Display name
- selpercatinib 80 MG Oral Tablet
- Full name
- selpercatinib 80 MG Oral Tablet
- Term type
- SY
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:05
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RETEVMO | SELPERCATINIB | Eli Lilly and Company | 7fa848ba-a59c-4144-9f52-64d090f4d828 | 2026-09-11 | Warnings, Adverse reactions | 2679815 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 7fa848ba-a59c-4144-9f52-64d090f4d828 | selpercatinib 80 MG Oral Tablet [PSN] · selpercatinib 80 MG Oral Tablet [SCD] · selpercatinib 80 MG Oral Tablet [SY] | 3 | 22 | These highlights do not include all the information needed to use RETEVMO safely and effectively. See full prescribing information for RETEVMO. RETEVMO ® (selpercatinib) capsules, for oral use RETEVMO ® (selpercatinib) tablets, for oral use Initial U.S. Approval: 2020 | 20251120 |